Arcturus Therapeutics Ltd. (ARCT)

Trade ARCT now with
3/18/2019 7:06:55 AM Arcturus Therapeutics Q4 Net Loss $1.0 Mln Or $0.10 Per Share
1/3/2019 7:03:47 AM Arcturus Therapeutics Appoints Andrew Sassine As CFO
1/2/2019 7:05:05 AM Arcturus Therapeutics Plans To Develop ARCT-810 For Treatment Of Ornithine Transcarbamylase Deficiency
11/7/2018 7:24:31 AM Arcturus Therapeutics Q3 Net Loss $4.3 Mln Or $0.42/Shr Vs $3.2 Mln Or $1.51/Shr Last Year
10/1/2018 7:10:56 AM Arcturus Therapeutics Q2 Loss Per Share $0.99 Vs Loss $0.54 Last Year
9/21/2018 7:02:29 AM Arcturus Therapeutics Appoints Kevin Skol As SVP Of Business Development & Alliance Management
9/20/2018 8:18:13 AM WBB Securities Upgrades Arcturus Therapeutics Ltd. (ARCT) To Strong Buy From Buy With $23 Price Target
8/28/2018 7:01:39 AM Arcturus Therapeutics Names Andrew Sassine Interim CFO
6/11/2018 11:07:41 AM WBB Securities Upgrades Arcturus Therapeutics Ltd. (ARCT) To Buy From Hold With $20 Price Target
5/31/2018 7:07:21 AM Arcturus Therapeutics Names Peter Farrell Chairman Of Board
5/29/2018 8:47:56 AM Arcturus Therapeutics Appoints Four Directors And Reaches Settlement Deal With Founder Joseph Payne
5/23/2018 10:20:04 PM California Federal Court Rules That Arcturus Likely To Succeed On Merits Of Claims Against Payne
5/2/2018 9:31:39 AM Israeli District Court Enjoins Attempt By Board To Dilute Shareholders Through Sale Of 24.9% Of Arcturus Share Capital
4/23/2018 9:33:16 AM Arcturus Founder Joseph Payne Dismisses Board’s Lawsuit As Desperate Entrenchment Tactic
4/20/2018 8:03:17 AM Arcturus Therapeutics Files Lawsuit Against Former CEO Joseph Payne And His Associates